USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ALBANY MOLECULAR RESEARCH, INC.
Address:
21 CORPORATE CIRCLE
ALBANY, NY 12203
Phone:
(518) 464-0279
URL:
N/A
EIN:
141742717
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $790,154.00 7

Award List:

26-Hydroxycholesterol--Therapy for Ctx and Restenosis

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Thomas D'ambra
Abstract:
26-Hydroxycholesterol is a naturally occurring metabolic product derived from cholesterol. Recent isuggest that this metabolite plays a role as a feedback inhibitor of cholesterol synthesis and may bregulation of LDL receptors. The absence of 26-hydroxycholesterol has been postulated to be the… More

DISCOVERY OF CDK INHIBITORS AS ANTITUMOR AGENTS

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Trova, michael p
Abstract:
The discovery of inhibitors of cyclin/cyclin dependent kinase (cdk) complexes is proposed which may have an antiprolifertive/antitumor effect of cells. Because overexpression of various cyclins have differential oncogenic potential, inhibitors will be assayed against a panel of cyclin/cdks. The… More

18 MC ANALOGS AS POTENTIAL ANTIADDICTIVE AGENTS

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$99,489.00
Agency:
HHS
Principal Investigator:
Pilling, Garry M
Abstract:
N/a

SYNTHESIS OF 18-METHOXYCORONARIDINE HYDROCHLORIDE

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Chihsin R. King
Abstract:
Not Available Ceradyne is proposing enhanced based armor (EBA) technology for protecting the AAAV. The EBA technology is based on several components (made of different materials), combined together to achieve enhanced capabilities. The proposal details alternative design solutions based on existing… More

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
DOE
Principal Investigator:
Joseph O. Rich, Senior Scientist
Abstract:
N/a

N/A

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$98,466.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

Biocatalytic Synthesis of Selective D1 Agonists

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$192,199.00
Agency:
HHS
Principal Investigator:
Peter C. Michels
Abstract:
DESCRIPTION (provided by applicant): "Drug addition is a complex illness. It is characterized by compulsive, at times uncontrollable drug craving, seeking, and use that persist even in the face of extremely negative consequences." As a consequence of the extraordinary personal,… More